NASDAQ · DRIO
Healthcare · Medical - Diagnostics & Research
$6.82
Down-$0.24 (-3.52%)
Updated Sep 11, 2026, 12:28 AM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 19 trading sessions · Daily adjusted prices
DRIO closed at $6.82 after 19 trading sessions, down 6.96% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $7.03 | $7.1676 | $6.80 | $6.82 | 6.32K |
| Sep 8, 2026 | $7.19 | $7.25 | $6.8686 | $7.03 | 10.33K |
| Sep 4, 2026 | $6.94 | $7.30 | $6.79 | $7.24 | 21.04K |
| Sep 3, 2026 | $7.33 | $7.43 | $6.87 | $6.98 | 29.61K |
| Sep 2, 2026 | $7.0799 | $7.62 | $7.0799 | $7.30 | 79.79K |
| Sep 1, 2026 | $7.15 | $7.57 | $6.79 | $7.02 | 40.02K |
| Aug 31, 2026 | $6.71 | $7.37 | $6.71 | $7.37 | 7.59K |
| Aug 28, 2026 | $6.81 | $7.00 | $6.45 | $6.77 | 17.9K |
| Aug 27, 2026 | $7.08 | $7.4902 | $6.77 | $6.77 | 21.11K |
| Aug 26, 2026 | $7.29 | $7.405 | $7.03 | $7.03 | 34.03K |
| Aug 25, 2026 | $7.10 | $7.7199 | $6.66 | $7.39 | 123.55K |
| Aug 24, 2026 | $7.13 | $7.54 | $7.13 | $7.21 | 10.31K |
| Aug 21, 2026 | $7.25 | $8.06 | $7.1001 | $7.49 | 4.84K |
| Aug 20, 2026 | $7.16 | $7.67 | $7.02 | $7.17 | 8.36K |
| Aug 19, 2026 | $7.55 | $7.8734 | $7.15 | $7.16 | 31.98K |
| Aug 18, 2026 | $7.535 | $7.635 | $7.03 | $7.18 | 6.37K |
| Aug 17, 2026 | $7.61 | $7.94 | $7.285 | $7.36 | 21.91K |
| Aug 14, 2026 | $7.24 | $7.915 | $7.24 | $7.585 | 5.32K |
| Aug 13, 2026 | $7.72 | $7.94 | $7.21 | $7.33 | 9.36K |
The latest Smart Investors Daily articles mentioning DRIO.
DRIO research
Company profile and research snapshot.
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 19, 2026 | Alliance Global Partners | Buy | — |
| Aug 12, 2026 | TD Cowen | Hold | — |
| Mar 20, 2026 | Stifel | Buy | — |
| May 19, 2025 | Litchfield Hills | Buy | — |
| Mar 11, 2025 | Stifel | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 19, 2026
Alliance Global Partners analyst Scott Henry initiates coverage on DarioHealth (NASDAQ:DRIO) with a Buy rating and announces Price Target of $12.
Benzinga · Aug 12, 2026
TD Cowen analyst Charles Rhyee maintains DarioHealth (NASDAQ:DRIO) with a Hold and lowers the price target from $11 to $8.
Yahoo · Aug 12, 2026
Net loss improved 39% amid shift to higher-margin B2B2C revenue.
Yahoo · Aug 11, 2026
DarioHealth Corp (DRIO) reports improved gross margins and reduced losses while navigating a revenue dip from pharma exit and implementation timing.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning DRIO.
